Glucose Variability of Farxiga and Invokana in a Patient with Type 2 Diabetes

Presentation Number: SAT 626
Date of Presentation: April 1st, 2017

Michael Spivak* and Naila M Goldenberg
Mercy Health Partners, Mason, OH

Abstract

Objective: Sodium glucose co-transporter inhibitors 2 (SGLT2) are a novel class of medications used for treatment of type 2 diabetes in adjunct to diet and exercise. Invokana (canagliflozin) is the first member of this class, which came on the market in 2013, and then shortly was joined by two more agents Faxiga (dapagliflosin) and Jardiance (empagliflozin). To this day there are no head to head studies evaluating these agents.

Case: We are presenting case of a 36 year old female with Type 2 diabetes. Patient’s glucose control on dapagliflozin and canagliflozin, with a background of Trulicity, was evaluated via continuous glucose monitor (CGMS) with one week wash out in between the agents.

Results: The results of CGMS demonstrate non-inferiority of dapagliflozin to canagliflozin; as well as possible superiority of dapagliflozin to canagliflozin in glucose level variability.

Conclusion: Even though the results of CGMS demonstrate non-inferiority of dapagliflozin to canagliflozin; as well as possible superiority of dapagliflozin to canagliflozin in glucose level variability; additional head to head studies with a larger pool of patients are required to evaluate efficacy of agents in SGLT2 class.

 

Nothing to Disclose: MS, NMG